Future REvascularization Evaluation in patients with Diabetes mellitus: Optimal management of Multivessel disease (FREEDOM)

Trial Profile

Future REvascularization Evaluation in patients with Diabetes mellitus: Optimal management of Multivessel disease (FREEDOM)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 08 Feb 2017

At a glance

  • Drugs Paclitaxel (Primary) ; Sirolimus (Primary)
  • Indications Coronary artery disease; Coronary artery restenosis
  • Focus Therapeutic Use
  • Acronyms FREEDOM
  • Most Recent Events

    • 17 Jan 2017 Results of post hoc secondary analysis published in the Journal of the American College of Cardiology
    • 09 Sep 2013 Planned number of patients changed from 2400 to 1900 as reported by ClinicalTrials.gov.
    • 08 Apr 2013 Planned End Date changed from 1 Dec 2011 to 1 Dec 2018 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top